Diagnosis and Management of Infantile Hemangioma

Table 15. Key outcomes in studies comparing propranolol and no propranolol
Author, Year
Age, Months
Comparison Groups
Location
Key Outcomes, n
(n)
Type
Quality
Perkins et al. 2014 149
G1: Propranolol era
2mg/kg/day, received
(25)
G2: Propranolol era, did
not receive (13)
G3: Pre-propranolol era
(20)
Quality: Fair
Hermans et al. 2011 145
G1: Propranolol 2.0 to
2.5/mg/kg/d in three
daily doses (20)
G2: Historical controls
(varied treatments) (20)
Quality: Fair
Age, Mean (range)
G1: 4.9 (2.0- 13.5)
G2: 4.9 (2.2-14.7)
G3: 4.8 (2.0-14.3)
Type, %
Superficial and
subcutaneous
G1+G2+G3: 100
Age, mean at start of
ulceration
G1: 2.3
G2: 2.7
Type, n:
Superficial nodular
G1: 14
Superficial macular
G1: 4
G1+G2:
nasal
G1+G2:
multiple
• 56% of G2 less likely to have any type of
invasive treatment when compared to G1
(HR: 0.44, 95% CI: 0.27 to 0.73)
• G2 and G3 were 35% less likely to have
any type of invasive treatment (HR: 0.65,
95% CI: 0.42 to 1.00) when compared to
G1
• 55% of G2 (HR: 0.45) less likely to have
surgical excision and 56% (HR: 0.44, 95%
CI: 0.27 to 0.78) less likely to have laser
treatment when compared to G1
• G2 and G3 61% (HR:0.39) less likely to
have surgical excision and 25% (HR: 0.75;
95% CI: 0.46 to 1.25) less likely to have
laser treatment when compared to G1
• Grade change assessed by two authors not
involved in treatment planning or medical
and surgical therapy
• Complete healing from ulceration
G1: 8.7 weeks
G2: 22.4 weeks
G1 vs.G2: p